What is Rolando Gutierrez-Esteinou’s role at Oryzon Genomics, S.A.?

Rolando Gutierrez-Esteinou has been appointed Chief Medical Officer, CNS Programs at Oryzon Genomics, S.A. His remit includes clinical development, regulatory strategy and activities connected with the company’s CNS programmes.

Where did Rolando Gutierrez-Esteinou work before joining Oryzon Genomics, S.A.?

Before joining Oryzon Genomics, S.A., Dr. Gutierrez-Esteinou served as Chief Medical Officer at Atai Life Sciences. He has also held senior leadership roles at Johnson & Johnson, Bristol Myers Squibb and Novartis, as well as in biotech and CRO organisations.

What clinical development experience does Rolando Gutierrez-Esteinou have at Oryzon Genomics, S.A.?

Oryzon Genomics, S.A. said Dr. Gutierrez-Esteinou’s experience covers clinical development from Phase I through Phase IV across schizophrenia, mood disorders, addiction and cognitive impairment. He has contributed to late-stage development programmes and regulatory submissions, including supplemental New Drug Applications and label expansions for Risperdal® and Abilify®.

What are Oryzon Genomics, S.A.’s plans for vafidemstat?

Oryzon Genomics, S.A. said it is preparing to move vafidemstat into Phase III clinical development for agitation and aggression in borderline personality disorder. The company also plans to expand its clinical development in agitation and aggression in autism spectrum disorder and in negative symptoms of schizophrenia.

What conditions is vafidemstat being developed to treat by Oryzon Genomics, S.A.?

Oryzon Genomics, S.A. is developing vafidemstat for agitation and aggression in borderline personality disorder, autism spectrum disorder and for negative symptoms of schizophrenia. The announcement identifies vafidemstat as the company’s lead CNS programme.

How does Oryzon Genomics, S.A. describe its business?

Oryzon Genomics, S.A. describes itself as a clinical-stage biopharmaceutical company and a global leader in epigenetics. The announcement focuses on its CNS programmes and the development of vafidemstat.

Why did Oryzon Genomics, S.A. appoint Rolando Gutierrez-Esteinou?

Oryzon Genomics, S.A. Chief Executive Officer Carlos Buesa said Dr. Gutierrez-Esteinou’s clinical expertise in psychiatry, late-stage CNS development experience and regulatory leadership would support preparations for vafidemstat’s Phase III development and further clinical expansion. Dr. Gutierrez-Esteinou said he joined because of Oryzon’s approach to CNS disorders and epigenetic treatments.

What did Rolando Gutierrez-Esteinou say about his priorities at Oryzon Genomics, S.A.?

Dr. Gutierrez-Esteinou said his aim is to lead a clinical programme that is scientifically rigorous, ethically sound and centred on patients. He also said the company would work with patients, investigators and regulators while addressing what he described as an unmet need in borderline personality disorder.

Who previously led the vafidemstat programme at Oryzon Genomics, S.A.?

Oryzon Genomics, S.A. recognised Dr. Michael Ropacki, who led the vafidemstat programme as CMO–CNS over the past six years. The company expressed its gratitude for his professionalism and work on the programme.

Where are Oryzon Genomics, S.A. shares identified as trading, and what is the ticker?

The announcement identifies Oryzon Genomics, S.A. as being based in Madrid, Spain and Cambridge, Massachusetts, United States, and gives its ISIN Code as ES0167733015 and ticker symbol as ORY.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon appoints Rolando Gutierrez-Esteinou as Chief Medical Officer for CNS programmes

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon appoints Rolando Gutierrez-Esteinou as Chief Medical Officer for CNS programmes

Q: What experience does Rolando Gutierrez-Esteinou bring to Oryzon Genomics, S.A.?

Oryzon Genomics, S.A. said Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist with more than 20 years of leadership experience in neuroscience and psychiatry-focused drug development. His experience includes late-stage clinical execution, regulatory strategy and pathways to market approval.

Published Thursday, 12 February 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Management change
Published: Thursday, 12 February 2026
Source announcement: oryzon.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ORY) announced on February 12, 2026, the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist with more than 20 years of leadership experience in neuroscience and psychiatry-focused drug development. He most recently served as Chief Medical Officer at Atai Life Sciences and has held senior roles at Johnson & Johnson, Bristol Myers Squibb and Novartis.

Oryzon said it is preparing to move vafidemstat into Phase III clinical development for agitation and aggression in borderline personality disorder, while expanding its clinical development in agitation and aggression in autism spectrum disorder and negative symptoms of schizophrenia. Dr. Gutierrez-Esteinou’s experience includes Phase I through Phase IV development and regulatory interactions with the FDA, EMA and PMDA. Oryzon also thanked Dr. Michael Ropacki, who led the vafidemstat program as CMO–CNS over the past six years.

Investor FAQs

Oryzon Genomics, S.A. announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. The company said he would support its CNS development activities, including the vafidemstat programme.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON announces appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
Published: Thursday, 12 February 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…